Elan, Eisai To Pay $214M Over Zonegran Marketing

Law360, New York (December 16, 2010, 1:56 PM ET) -- The U.S. government has finalized a $203.5 million criminal and civil settlement with Irish drugmaker Elan Corp. PLC over off-label marketing of epilepsy drug Zonegran, as well as revealed an $11 million False Claims Act settlement with the drug's current owner Eisai Co. Ltd.

The settlement with Tokyo-based Eisai resolves the government's claims in the U.S. District Court for the District of Massachusetts that the company violated the FCA and related state statutes by continuing to promote Zonegran for off-label uses after purchasing the drug from...
To view the full article, register now.